Why ICU patients may need different antiseizure medication strategies
Antiseizure medication dosing and monitoring in the intensive care unit: a practical narrative review.
AI Summary
This narrative review explains why antiseizure medications (ASMs) can behave differently in the intensive care unit than in routine outpatient care. Organ dysfunction, severe illness, multiple medications, and supportive devices can all change drug exposure, making standard dosing less reliable. The review covers 15 ASMs, including cannabidiol, and discusses dosing, pharmacokinetics, drug interactions, and therapeutic drug monitoring.
The authors emphasize that ICU treatment requires an individualized approach, particularly when patients have kidney or other organ problems or are receiving renal replacement therapy, ECMO, or plasmapheresis. For people taking cannabidiol or other ASMs who become critically ill, the broader practical message is that clinicians need a complete medication history and may need to adjust treatment and monitor drug levels. The abstract reports no quantitative treatment outcomes; it presents a practical synthesis of existing literature rather than a new clinical trial.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.